[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracerebral-hemorrhage-basal-ganglia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracerebral-hemorrhage-basal-ganglia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,62,97,122,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":38,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100597086","phase-1-psychedelic-healing-adjunct-therapy-harnessing-opened-malleability-100597086",false,"NCT07053917","Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","PHATHOM","Inclusion Criteria:\n\n* Over age 18 years, inclusive.\n* Ischemic or hemorrhagic stroke confirmed by CT or MRI, at least 12 months prior to admission date\n* Ability to give informed consent and understand the tasks involved.\n* Agree that, for the study duration, will refrain from: (1) No new prescription medications during the time of the study without approval of the study team, (2) taking any herbal supplement (except with prior approval of the research team), (3) taking any nonprescription medications with the exception of: 1. non-steroidal anti-inflammatory drugs. 2. acetaminophen. 3. vitamins. 4. or other over-the-counter medications approved by the research team\n* Are willing to follow restrictions and guidelines concerning medications, consumption of food, beverages, and nicotine the night before and just prior to psilocybin administration.\n* Agree to have transportation other than driving themselves home or to where the participants are staying after the administration of psilocybin.\n* Are willing to be contacted via telephone for all necessary telephone contacts.\n* Must have a negative pregnancy test if able to bear children.\n* Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal.\n* Must agree to inform the investigators within 48 hours of any new medical conditions and procedures.\n* Are proficient in speaking and reading English.\n* Agree to have all clinical visit sessions recorded to audio and video.\n* Agree to not participate in any other interventional clinical trials during the duration of this study.\n\nExclusion Criteria:\n\n* Taking one of the following medications in the 30 days prior to psilocybin administration:\n\n  1. selective serotonin reuptake inhibitor (SSRI)\n  2. Serotonin-norepinephrine reuptake inhibitors (SNRI)\n  3. Buproprion\n  4. Valproic acid\n  5. Zolpidem\n  6. Trazodone\n  7. Carbamazepine.\n  8. tricyclic antidepressants\n  9. Monoamine Oxidase Inhibitors\n  10. Mirtazapine\n\n  l. Lithium m. Buspirone n. Atypical antipsychotics o. Zolpidem p.Carbamazepine q. Clonazepam r. Gabapentin s. Lamotrigine t. Levetiracetam u. Phenobarbital v. Phenytoin w. Topiramate x. Valproic Acid y. Zonisamide\n* History of medically significant suicide attempt.\n* Evidence of acute cardiac dysfunction as evidenced by either elevated troponin or EKG changes within 48 hours of administration.\n* Systolic blood pressure that is greater than 150 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Diastolic blood pressure that is greater than 100 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Systolic blood pressure is less than 90 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Diastolic blood pressure is less than 30 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Systolic blood pressure exceeds 160 mmHg or is less than 90 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Diastolic blood pressure exceeds 100 mmHg or is less than 30 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Cognitive impairment that, in the estimation of the study team, would preclude the use of the MindPod Dolphin.\n* History of physical or neurological condition that interferes with study procedures or assessment of motor function (e.g. severe arthritis, severe neuropathy, Parkinson's disease).\n* Social and\u002For personal circumstances that interfere with ability to perform follow up assessments.\n* Are pregnant or nursing.\n* Weigh less than 48 kg.\n* Are not able to give adequate informed consent.\n* Are actively abusing opioids, cocaine, Phencyclidine (PCP), amphetamines, or alcohol.\n* Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-5) criteria for moderate or severe substance use disorder\n* Diagnosis of schizophrenia, history of prior psychosis, anxiety requiring hospitalization, or Type 1 bipolar.\n* Hypernatremia\n* Hypokalemia (but can have received repletion during the prior 24 hours)\n* Hyperkalemia\n* Glomerular filtration rate of \\\u003C 30 ml\u002Fmin\n* Elevated of white blood cell count\n* Hemoglobin \\\u003C 7 g\u002Fdl\n* Platelet count \\\u003C 100,000 g\u002Fdl\n* Acute cardiac dysfunction demonstrated by either troponin elevation (chronic elevation is acceptable), or EKG changes suggestive of acute coronary syndrome.\n* Active suicidal ideation as assess by the C-SSRS.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.",[26,27,28,29,30,31,32,33,34,35,36,37],"Stroke","Chronic Stroke","Intracerebral Haemorrhage","Intracerebral Haemorrhage (ICH)","Intracerebral Hemorrhage Basal Ganglia","Ischemic Stroke","Ischemic Stroke and Hemorrhagic Stroke","Hemiparesis After Stroke","Hemiplegia Following Ischemic Stroke","Hemiplegia and Hemiparesis","Hemiplegia and\u002For Hemiparesis Following Stroke","Middle Cerebral Artery Stroke",[39,40,41,42,43,44,45,46,47,48],"psychedelic","stroke","chronic stroke","intracerebral hemorrhage","stroke recovery","motor recovery","poststroke recovery","poststroke motor recovery","hemiparesis recovery","psychedelic safety","RECRUITING","2026-02-11",{"date":52,"type":53},"2026-02-13","ACTUAL",{"date":55,"type":53},"2026-02-09",{"date":57,"type":20},"2027-03",{"name":59,"class":60},"Johns Hopkins University","OTHER",1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":61},"100617468","ai-assisted-transcranial-duplex-sonography-for-early-detection-of-intracerebral-haemorrhage-hyper-ai-scan-100617468","NCT07319013","AI-assisted Transcranial Duplex Sonography for Early Detection of Intracerebral Haemorrhage: HYPER-AI-SCAN","HYPER-AI-SCAN: HYPER-acute AI-assisted Sonographic Cerebral Hemorrhage Assessment Network","Inclusion Criteria:\n\n* Adult patients (age ≥18 years).\n* Clinical diagnosis of acute stroke (ischemic or intracerebral hemorrhage).\n* Able to undergo transtemporal transcranial ultrasound according to the standardized protocol (no clinical instability)\n* Informed consent obtained from the patient or legally authorized representative, per local regulations.\n\nExclusion Criteria:\n\n* Infratentorial hemorrhage (e.g., cerebellar or brainstem hemorrhage), due to limitations of transtemporal insonation.\n* Isolated subarachnoid hemorrhage without parenchymal involvement.\n* Hemodynamic instability or medical conditions requiring immediate life-saving intervention that preclude safe ultrasound recording.\n* Known skull defects or prior craniectomy on the side required for contralateral insonation.\n* Any condition that, in the opinion of the investigators, would interfere with protocol adherence or data accuracy.",{"count":70,"type":20},500,"OBSERVATIONAL","The goal of this observational study is to evaluate whether transcranial Doppler ultrasound, combined with artificial intelligence (AI), can help identify intracerebral haemorrhage (ICH) in people with acute stroke (both men and women, adults of all ages) within 48 hours of symptom onset.\n\nThe main questions it aims to answer are:\n\nIs it feasible to perform standardized protocol transcranial ultrasound in acute stroke patients? Can AI models trained on ultrasound images accurately distinguish haemorrhagic stroke (\"ICH suspected\") from non-haemorrhagic stroke? There is no comparison group, because all participants will undergo both CT (as standard care) and ultrasound (research imaging), and the AI models will compare their ultrasound-based predictions against CT-confirmed diagnoses.\n\nParticipants will:\n\nundergo a non-invasive transcranial ultrasound scan after CT confirms the type of stroke allow researchers to collect coded ultrasound images for AI model training provide clinical and imaging information (already collected as part of routine care) to help evaluate factors related to diagnostic accuracy No treatments or changes to clinical care will be introduced as part of the study.",[26,74,30,28],"Intracerebral Hemorrhage",[40,76,31,77,78,79,80,81,82,83,84,85,86,87],"intracerebral hemorrage","Hemorrhagic Stroke","transcranial ultrasound","Transcranial Doppler","Portable Ultrasound","Neurosonology","Artificial Intelligence","Machine Learning","Diagnostic Accuracy","Prehospital Care","Feasibility Study","Deep Learning","2025-12-19",{"date":90,"type":53},"2026-01-06",{"date":92,"type":53},"2025-03-14",{"date":94,"type":20},"2027-06",{"name":96,"class":60},"Hospital Universitari Vall d'Hebron Research Institute",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":61},"100611005","minimally-invasive-surgery-for-patients-with-spontaneous-deep-intracerebral-hemorrhage-100611005","NCT07234955","Minimally Invasive Surgery For Patients With Spontaneous Deep Intracerebral Hemorrhage","Evaluation Of The Efficacy And Safety Of Minimally Invasive Surgery In Patients With Spontaneous Deep Intracerebral Hemorrhage","MISDIH","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Spontaneous basal ganglia intracerebral hemorrhage confirmed by non-contrast CT scan\n* Hematoma volume 30-80 mL (ABC\u002F2 method)\n* Time from onset\u002Flast known well ≤ 72 hours\n* Glasgow Coma Scale (GCS) score 5-14 at admission\n* Pre-stroke modified Rankin Scale (mRS) score 0-1\n\nExclusion Criteria:\n\n* Secondary intracerebral hemorrhage due to trauma, tumor, vascular malformation, aneurysm, or hemorrhagic transformation of ischemic stroke\n* Infratentorial hemorrhage (brainstem or cerebellum)\n* Primary thalamic hemorrhage\n* Extensive intraventricular hemorrhage (\\>50% of one lateral ventricle)\n* NIHSS \\\u003C 5 at admission\n* Bilateral fixed dilated pupils without light reflex\n* Decerebrate posture\n* Platelet count \\\u003C 75,000\u002FµL\n* INR \\> 1.4 after correction\n* Ongoing anticoagulation that cannot be rapidly reversed\n* Indication for long-term anticoagulation within 5 days of onset\n* End-stage renal disease\n* End-stage liver disease\n* Presence of mechanical heart valve\n* Any comorbidity with life expectancy \\\u003C 6 months\n* Patient or legal representative unwilling or unable to provide written informed consent","80 Years",{"count":107,"type":20},300,"This observational cohort study evaluates the safety and effectiveness of minimally invasive surgery (MIS) compared with standard medical management in adults with spontaneous deep intracerebral hemorrhage. Consecutive patients admitted to People's Hospital 115 and Tam Anh General Hospital will be enrolled within 72 hours of onset. Clinical and imaging data will be collected prospectively, and outcomes including survival and functional status will be assessed through 180 days.",[30,28],[111],"Deep Intracerebral Hemorrhage","2025-11-14",{"date":114,"type":53},"2025-11-19",{"date":116,"type":53},"2025-09-08",{"date":118,"type":20},"2028-09-01",{"name":120,"class":121},"Huynh Quoc Huy","OTHER_GOV",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":61},"100587176","phase-4-neuroendoscopic-hematoma-evacuation-combined-with-methylprednisolone-sodium-succinate-in-the-treatment-of-basal-ganglia-intracerebral-hemorrhage-at-the-early-stage-100587176","NCT06924983","Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Basal Ganglia Intracerebral Hemorrhage at the Early Stage","A Multicenter, Randomized Controlled Clinical Trial on the Efficacy and Safety of Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Basal Ganglia Intracerebral Hemorrhage at the Early Stage.","NEMP-BGH","Inclusion Criteria:\n\n1. Aged between 18 and 80 years old.\n2. Diagnosed with spontaneous intracerebral hemorrhage (ICH) through cranial CT scan, with the bleeding site located in the basal ganglia region.\n3. Calculate the hematoma volume based on the cranial CT scan. The volume should range from 30 to 80 ml, and the shift of the mid - line structure at the pineal gland level should be less than 3 mm. The formula for calculating the hematoma volume is V (cm³)=A \\* B \\* C \\* 1\u002F2, where A represents the longest diameter (cm) of the largest hematoma layer in the horizontal position of the plain CT scan, B is the widest diameter (cm) of the hematoma perpendicular to A on this plane, and C is the thickness (cm) of the hematoma shown in the CT images.\n4. The time from the onset of the disease to randomization should be within 24 hours. If the actual onset time is unclear, the onset time will be regarded as the time when the subject was last confirmed to be in good health.\n5. The National Institutes of Health Stroke Scale (NIHSS) score should be ≥ 6 points at the time of randomization.\n6. The Glasgow Coma Scale (GCS) score should range from 5 to 14 points at the time of randomization.\n7. The modified Rankin Scale (mRS) score before the onset of the disease should be 0 - 1 points.\n8. The patient and their legal representative should sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Hemorrhage in other locations (such as hemorrhage in infratentorial regions like the lobes, thalamus, brainstem, or cerebellum).\n2. Hemorrhage caused by other reasons (for example, hemorrhage due to aneurysm, arteriovenous malformation, brain trauma, brain tumor, hemorrhagic transformation of large-area cerebral infarction, hemorrhage caused by amyloid angiopathy, hemorrhage resulting from coagulation disorders) or combined with aneurysm, arteriovenous malformation, brain trauma, brain tumor, large-area cerebral infarction, amyloid angiopathy, severe coagulation disorders.\n3. Patients with intraventricular hemorrhage or those with intracerebral hemorrhage (ICH) breaking into the ventricles and considered to require external ventricular drainage.\n4. A history of any parenchymal brain hemorrhage or other intracranial subarachnoid, subdural, or epidural hemorrhage and a history of relevant surgeries within the recent 30 days.\n5. Patients with genetic or acquired bleeding tendencies, coagulation disorders such as deficiency of coagulation factors.\n6. Platelet count \\\u003C 75 × 10⁹\u002FL.\n7. Undergoing anticoagulant drug treatment with warfarin, dabigatran, or rivaroxaban, etc. within one week before enrollment, and having an international normalized ratio (INR) \\> 1.4.\n8. Expected to require long-term anticoagulation and antiplatelet therapy.\n9. A history of previous internal hemorrhage, with risks of gastrointestinal bleeding (such as gastrointestinal ulcers), genitourinary bleeding, or respiratory tract bleeding that has not been fully controlled.\n10. Myocardial infarction occurred within the recent 30 days.\n11. Known to have a high embolism risk, including patients with mechanical heart valves implanted in the body, a history of left heart thrombus, mitral stenosis accompanied by atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. Atrial fibrillation without mitral stenosis is eligible.\n12. Severe liver function impairment, with alanine aminotransferase (ALT) \\> 3 times the upper limit of the normal range, or aspartate aminotransferase (AST) \\> 3 times the upper limit of the normal range. Severe renal insufficiency, with a glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73 m².\n13. Patients with Alzheimer's disease or mental disorders who are unable to complete the follow-up plan as required.\n14. Complicated by any severe diseases that, upon evaluation, may interfere with the trial results, including diseases of the respiratory system, circulatory system, digestive system, genitourinary system, endocrine system, immune system, and hematopoietic system, etc.\n15. Allergic to drugs or devices related to the operation.\n16. Pregnant or lactating women, or those planning to become pregnant within one year.\n17. In the terminal stage of any disease with an expected lifespan of less than 6 months.\n18. Currently participating in other clinical trials or having been previously enrolled in this trial.\n19. The patient or his\u002Fher legal guardian is unwilling to sign the written informed consent form.",{"count":131,"type":20},100,[133],"PHASE4","The aim of this trial is to investigate whether neuroendoscopic hematoma evacuation combined with early use of methylprednisolone sodium succinate can improve the efficacy and safety in the treatment with that of simple neuroendoscopic surgery alone for patients with spontaneous basal ganglia intracerebral hemorrhage within 24 hours after the onset.",[26,30,136,137],"Methylprednisolone","Surgery","NOT_YET_RECRUITING","2025-04-10",{"date":141,"type":53},"2025-04-13",{"date":143,"type":20},"2025-05-01",{"date":145,"type":20},"2027-01-31",{"name":147,"class":60},"Yong Jiang",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":158,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100480736","efficacy-and-safety-of-neuroendoscopic-surgery-for-intracerebral-hemorrhage-100480736","NCT05539859","Efficacy and Safety of NeuroEndoscopic Surgery for IntraCerebral Hemorrhage","Efficacy and Safety of NeuroEndoscopic Surgery for IntraCerebral Hemorrhage: a Randomised, Controlled, Open-label, Blinded Endpoint Trial","NESICH","Inclusion Criteria:\n\n1. Age 18-80 years, either sex.\n2. Time from onset to the first diagnostic CT within 24 hours (for those without bystanders and with unknown onset time, use the last known time the patient was in good condition)\n3. Deep (external capsule, putamen, internal capsule, caudate nucleus) supratentorial cerebral hemorrhage with a hematoma volume ≥ 25 ml.\n4. Stability of the hematoma determined by two CT scans at different times after onset. If the hematoma enlarges 5ml then the stability of the hematoma can be detected by CT again after 6 hours until the randomization time window is closed.\n5. Pre-randomization GCS score of 5-14 and\u002For NIHSS score of ≥6.\n6. Pre-onset Modified Rankin Scale (mRS) score 0 or 1.\n7. Blood pressure recorded 6 hours prior to randomization consistently controlled at 180 mmHg or less.\n8. Randomization completed within 24 hours after the first diagnostic CT, and surgical intervention should be performed as soon as possible, no later than 6 hours after randomization, that is to say, surgery should be performed no later than 54 hours after onset.\n9. Informed and voluntarily signed informed consent by the patient or family.\n\nExclusion Criteria:\n\n1. Hemorrhage clinically diagnosed as a result of cerebral aneurysm, cerebrovascular malformation, moyamoya disease, traumatic brain injury, brain tumor, hemorrhagic transformation of a large cerebral infarct, coagulation dysfunction.\n2. Lobar hemorrhages, thalamic hemorrhages, primary ventricular hemorrhages, cerebellum hemorrhages and brain stem hemorrhages.\n3. Hematoma involving the midbrain, with dilated or unresponsive pupils.\n4. Hematoma producing life-threatening occupying effects (e.g., CT showing midline deviation of more than 1 cm, loss of cisterna ambiens) or patients who are extremely unstable and unfit for enrollment.\n5. Platelet count \\\u003C100×10\\^9\u002FL, international normalized ratio (INR) \\>1.4.\n6. Hematoma extension to ventricle and completely blocked the third or fourth ventricle.\n7. Recent history of cerebral hemorrhage (less than 1 year).\n8. Severe hepatic impairment with ALT 3 times the upper limit of normal, or AST 3 times the upper limit of normal. Severe renal insufficiency with glomerular filtration rate less than 30 ml\u002Fmin\u002F1.73 m2.\n9. Blood pressure not effectively controlled to less than 180 mmHg despite aggressive antihypertensive therapy prior to randomization.\n10. Patients with severe advanced cognitive impairment (e.g. AD) or psychiatric disorders who are unable to complete the follow-up program as required.\n11. Comorbid other serious diseases such as respiratory, circulatory, digestive, urological, endocrine, immune and hematologic disorders.\n12. Pregnant or lactating women, or those who expect to become pregnant within one year.",{"count":157,"type":20},560,[159],"NA","To compare the efficacy and safety of neuroendoscopic hematoma removal and standard conservative treatment for patients with spontaneous supratentorial deep intracerebral hemorrhage.",[30],[163,164],"Intracerebral hemorrhage","NeuroEndoscopic Surgery","2024-05-08",{"date":167,"type":53},"2024-05-10",{"date":169,"type":53},"2022-11-18",{"date":171,"type":20},"2026-09-01",{"name":173,"class":60},"Southwest Hospital, China",4]